 Atreca announced preliminary results using ATRC-101 in a phase 1b study treating patients with advanced solid tumors. One expansion cohort will include the combination of ATRC-101 and Keytruda which already began, the 2nd expansion cohort is expected to start Q4 2021 which includes ATRC-101 and chemotherapy. 